A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors by Ann W. Silk, Biren Saraiya, Roman Groisberg, Nancy Chan, Kristen Spencer, Eugenia Girda, Weichung Shih, Marisa Palmeri, Tracie Saunders, Robert M. Berman, Vlad Coric, Suzie Chen, Andrew Zloza, Joshua Vieth, Janice M. Mehnert, Jyoti Malhotra

Get full text

A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma by Ann W. Silk, Ann W. Silk, Ann W. Silk, Ann W. Silk, Brendan Curti, Jennifer Bryan, Jennifer Bryan, Tracie Saunders, Weichung Shih, Michael P. Kane, Phoebe Hannon, Christopher Fountain, Jessica Felcher, Andrew Zloza, Andrew Zloza, Andrew Zloza, Howard L. Kaufman, Howard L. Kaufman, Howard L. Kaufman, Howard L. Kaufman, Howard L. Kaufman, Janice M. Mehnert, Janice M. Mehnert, Janice M. Mehnert, David F. McDermott, David F. McDermott

Get full text

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration by Mark N. Stein, Jyoti Malhotra, Rohinton S. Tarapore, Usha Malhotra, Ann W. Silk, Nancy Chan, Lorna Rodriguez, Joseph Aisner, Robert D. Aiken, Tina Mayer, Bruce G. Haffty, Jenna H. Newman, Salvatore M. Aspromonte, Praveen K. Bommareddy, Ricardo Estupinian, Charles B. Chesson, Evita T. Sadimin, Shengguo Li, Daniel J. Medina, Tracie Saunders, Melissa Frankel, Aparna Kareddula, Sherrie Damare, Elayne Wesolowsky, Christian Gabel, Wafik S. El-Deiry, Varun V. Prabhu, Joshua E. Allen, Martin Stogniew, Wolfgang Oster, Joseph R. Bertino, Steven K. Libutti, Janice M. Mehnert, Andrew Zloza

Get full text